CA2368614C - Improved cancer treatment with temozolomide - Google Patents

Improved cancer treatment with temozolomide Download PDF

Info

Publication number
CA2368614C
CA2368614C CA002368614A CA2368614A CA2368614C CA 2368614 C CA2368614 C CA 2368614C CA 002368614 A CA002368614 A CA 002368614A CA 2368614 A CA2368614 A CA 2368614A CA 2368614 C CA2368614 C CA 2368614C
Authority
CA
Canada
Prior art keywords
temozolomide
day
period
days
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002368614A
Other languages
English (en)
French (fr)
Other versions
CA2368614A1 (en
Inventor
Mohamed H. Ragab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CA2368614A1 publication Critical patent/CA2368614A1/en
Application granted granted Critical
Publication of CA2368614C publication Critical patent/CA2368614C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002368614A 1999-03-30 2000-03-27 Improved cancer treatment with temozolomide Expired - Fee Related CA2368614C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28134899A 1999-03-30 1999-03-30
US09/281,348 1999-03-30
PCT/US2000/008079 WO2000057867A2 (en) 1999-03-30 2000-03-27 Improved cancer treatment with temozolomide

Publications (2)

Publication Number Publication Date
CA2368614A1 CA2368614A1 (en) 2000-10-05
CA2368614C true CA2368614C (en) 2008-07-22

Family

ID=23076905

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002368614A Expired - Fee Related CA2368614C (en) 1999-03-30 2000-03-27 Improved cancer treatment with temozolomide

Country Status (18)

Country Link
EP (1) EP1165071B1 (https=)
JP (2) JP2002540148A (https=)
CN (2) CN1345240A (https=)
AR (1) AR023185A1 (https=)
AT (1) ATE310515T1 (https=)
AU (1) AU780892B2 (https=)
BR (1) BR0009380A (https=)
CA (1) CA2368614C (https=)
DE (1) DE60024243T2 (https=)
DK (1) DK1165071T3 (https=)
ES (1) ES2251987T3 (https=)
HK (1) HK1044111B (https=)
HU (1) HUP0200805A3 (https=)
NO (1) NO330651B1 (https=)
NZ (1) NZ536302A (https=)
TW (1) TWI276434B (https=)
WO (1) WO2000057867A2 (https=)
ZA (1) ZA200107736B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100366249C (zh) * 2002-09-29 2008-02-06 天津帝士力投资控股集团有限公司 一种替莫唑胺控释给药系统
CN1742723A (zh) * 2004-09-02 2006-03-08 天津倍方科技发展有限公司 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途
CN1299772C (zh) * 2004-10-14 2007-02-14 孔庆忠 一种抗癌药物组合物
EP1830845A2 (en) * 2004-11-09 2007-09-12 Shering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level
EP1976515A2 (en) * 2006-01-17 2008-10-08 Abbott Laboratories Combination therapy with parp inhibitors
CN103751186B (zh) * 2006-04-05 2016-08-24 欧科生医股份有限公司 药物制剂：8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的盐及用其治疗的方法
AR061618A1 (es) * 2006-06-26 2008-09-10 Schering Corp Formas de dosificacion unitaria de temozolomida
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
KR101438036B1 (ko) * 2006-09-29 2014-09-04 씨아이피엘에이 엘티디. 테모졸로미드 및 유사체의 개선된 제조방법
JP6112512B2 (ja) * 2010-12-01 2017-04-12 レクシ ファーマ インコーポレイテッド 難治性癌を治療するための方法
CN102526038B (zh) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
CN107397735B (zh) * 2017-07-28 2020-07-10 东曜药业有限公司 一种替莫唑胺药物组合物及其制备方法和应用
CN117338750A (zh) * 2023-11-24 2024-01-05 郑州德迈药业有限公司 一种替莫唑胺制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE229343T1 (de) * 1995-10-04 2002-12-15 Schering Corp Kombination von temozolomide und alpha-interferon zur behandlung von fortgeschrittenem krebs
CA2184545A1 (en) * 1996-07-31 1998-02-01 Pascale Reidenberg Cancer treatment with temozolomide
CA2184546A1 (en) * 1996-07-31 1998-02-01 Margaret H. Dugan Method for treating pediatric high grade astrocytoma including brain stem glioma

Also Published As

Publication number Publication date
DE60024243D1 (de) 2005-12-29
BR0009380A (pt) 2001-12-26
AU3924400A (en) 2000-10-16
ATE310515T1 (de) 2005-12-15
EP1165071B1 (en) 2005-11-23
HUP0200805A3 (en) 2004-07-28
NO330651B1 (no) 2011-05-30
AU780892B2 (en) 2005-04-21
WO2000057867A3 (en) 2001-04-19
CN1345240A (zh) 2002-04-17
DE60024243T2 (de) 2006-08-17
TWI276434B (en) 2007-03-21
JP2007169297A (ja) 2007-07-05
HUP0200805A2 (hu) 2002-07-29
NZ536302A (en) 2006-05-26
DK1165071T3 (da) 2006-02-20
ES2251987T3 (es) 2006-05-16
HK1044111B (en) 2006-02-24
EP1165071A2 (en) 2002-01-02
CA2368614A1 (en) 2000-10-05
HK1044111A1 (en) 2002-10-11
ZA200107736B (en) 2003-02-26
JP2002540148A (ja) 2002-11-26
NO20014725D0 (no) 2001-09-28
WO2000057867A2 (en) 2000-10-05
CN102160864A (zh) 2011-08-24
NO20014725L (no) 2001-11-13
AR023185A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
US5939098A (en) Cancer treatment with temozolomide
JP2007169297A (ja) テモゾロミドを用いる改善された癌処置
US6346524B1 (en) Cancer treatment with temozolomide
US7910580B2 (en) Enhancement of effectiveness of 5-Fluorouracil in treatment of tumor metastases and cancer
TW202333675A (zh) 用於治療癌症之組合療法之用途
US4792558A (en) Castanospermine for inhibiting tumor metastasis
US5824346A (en) Combination therapy for advanced cancer
CA2184545A1 (en) Cancer treatment with temozolomide
CA2435921A1 (en) Method of cancer therapy
EP1208840B1 (en) Combination of fluorouracil and a methylol transfer agent for the treatment of tumor metastases and cancer
MXPA01009926A (en) Improved cancer treatment with temozolomide
JP2003521497A (ja) 癌のための組み合せ治療
ES2393398T3 (es) Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer
US5942247A (en) Method for treating pediatric high grade astrocytoma including brain stem glioma
DeMario et al. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days
CA2229141A1 (en) Combination therapy for advanced cancer comprising temozolomide and cisplatin
US20090221615A1 (en) Combination anti-cancer agents
CN100402029C (zh) 包含埃坡霉素衍生物和烷化剂的组合
Blumenreich et al. A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies
CN111419853B (zh) 一种治疗乳腺癌的葫芦素与依鲁替尼组合物
CA2184546A1 (en) Method for treating pediatric high grade astrocytoma including brain stem glioma
Chan et al. An A, B, C, D of cancer chemotherapy
Lokich Cancer chemotherapy by constant infusion
Score Effectivetiess confirmed
MXPA98001585A (es) Terapia combinada para el cancer avanzado, que comprende la temozolomida y el cisplatin

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140327